Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study

Human Papillomavirus-Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02323997

Acronym

CIN3+plus

Enrollment

767

Registered

2014-12-24

Start date

2015-01-31

Completion date

2016-05-31

Last updated

2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

HPV, cervical cancer, human papillomavirus, cervical pre-cancer, cervical neoplasia

Brief summary

This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the study. * Participant is literate in German, French, Italian or English. * Female, aged 18 years or above. * Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix. * Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Human papillomavirus presence and type	2 years

Countries

Switzerland

Outcome results